Document Detail


Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy.
MedLine Citation:
PMID:  20921280     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To make the specificity of fluorodesoxyglucose ((18)FDG) positron emission tomography (PET) precise, in the follow-up of patients with adrenal cancer.
DESIGN: This single centre retrospective study assessed the frequency and outcome of (18)FDG uptake in the remaining adrenal glands after adrenalectomy for adrenocortical carcinoma (ACC) or malignant phaeochromocytoma (PH).
RESULTS: Two hundred and ten (18)FDG PET scans in 62 ACC patients, all under 1,ortho-1,para'-dichloro-diphenyl-dichloro-ethane (o,p'-DDD) treatment, and 30 (18)FDG PET scans in 8 PH patients were reviewed. Abnormal (18)FDG uptake in the remaining adrenal glands was found in 19 (8%) (18)FDG PET scans, in 10 (16%) ACC patients and in none of the PH patients. (18)FDG uptake was found in 4% of the patients before the onset of o,p'-DDD, in 29% of the patients 0-6 months after the onset of o,p'-DDD (P=0.05), in 26% of the patients 6-12 months (P=0.072) after the onset of o,p'-DDD and in 14% of the patients 12-24 months after the onset of o,p'-DDD. It was never found later than 24 months after the onset of o,p'-DDD. Adrenal glands with (18)FDG uptake were normal on computed tomography scans with i.v. contrast agent in all cases. (18)FDG uptake in the remaining adrenal glands decreased and disappeared on subsequent FDG PET imaging in eight of the patients with follow-up available.
CONCLUSIONS: (18)FDG uptake in the remaining adrenal glands occurred in 14-29% of the patients followed for ACC within 24 months after adrenalectomy and onset of o,p'-DDD. This uptake is transient and should not be considered as suspicious for malignancy.
Authors:
S Leboulleux; D Deandreis; C Escourrou; A Al Ghuzlan; F Bidault; A Aupérin; J P Travagli; J Lumbroso; M Schlumberger; E Baudin
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-10-04
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  164     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-14     Completed Date:  2011-01-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  89-94     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. leboulleux@igr.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Neoplasms / metabolism,  radionuclide imaging*,  surgery
Adrenal Glands / metabolism*,  radionuclide imaging*
Adrenalectomy*
Adrenocortical Carcinoma / metabolism,  radionuclide imaging*,  surgery
Adult
Aged
Female
Fluorodeoxyglucose F18 / diagnostic use*,  metabolism
Follow-Up Studies
Humans
Male
Middle Aged
Pheochromocytoma / metabolism,  radionuclide imaging*,  surgery
Positron-Emission Tomography* / methods
Radiopharmaceuticals / diagnostic use
Retrospective Studies
Sensitivity and Specificity
Time Factors
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How the adoption of impression management goals alters impression formation.
Next Document:  The V?14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved ...